Search

everythinglearnresearchcommunity

for

Search:↓

The user discusses using finasteride and dutasteride for hair regrowth, avoiding minoxidil due to side effects and inconvenience. They find these treatments effective without needing minoxidil.

Minoxidil, finasteride, and RU58841 are discussed as treatments for androgenetic alopecia (AGA). The conversation questions their effectiveness and whether they are scams.

Stemoxydine, a hair loss treatment, is reportedly discontinued, with some users suggesting alternatives like a rebranded version with resveratrol that may enhance Minoxidil. Some users express dissatisfaction with the discontinuation and question the product's value.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

The conversation discusses hair regrowth treatments, specifically using a combination of oral and topical minoxidil, oral and topical dutasteride, and PRP. There is skepticism about the authenticity of the results, with some users questioning the changes in hair and skin appearance.

The user has been using finasteride, ketoconazole shampoo, oral minoxidil, and minoxidil foam for hair loss but feels their hair is not as thick as desired. They have stopped using RU58841 due to lack of results and are concerned about hair miniaturization despite these treatments.

The user shared positive hair regrowth results using Minoxidil 5% and stinging nettle root over six months. They avoided finasteride due to concerns but are open to using it if needed.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.